Destiny Pharma PLC Exercise of Options and Total Voting Rights (2616F)
07 7월 2023 - 3:00PM
UK Regulatory
TIDMDEST
RNS Number : 2616F
Destiny Pharma PLC
07 July 2023
Destiny Pharma plc
("Destiny Pharma" or "the Company")
Exercise of Options and Total Voting Rights
Brighton, United Kingdom - 07 July 2023 - Destiny Pharma (AIM:
DEST), a clinical stage innovative biotechnology company focused on
the development of novel medicines that can prevent life
threatening infections, announces that it has issued and allotted
7,946 new ordinary shares of 1 pence each in the capital of the
Company (the "New Ordinary Shares") following an exercise of share
options by an employee.
Application will be made to the London Stock Exchange for the
New Ordinary Shares to be admitted to trading on AIM, with dealings
expected to commence on 12 July 2023 ("Admission").
Following Admission, the Company will have a total of 95,271,863
Ordinary Shares in issue. Shareholders may use this figure of
95,271,863 Ordinary Shares as the denominator for the calculations
by which they will determine if they are required to notify their
interest in, or a change to their interest in, the share capital of
the Company under the FCA's Disclosure Guidance and Transparency
Rules.
For further information, please contact:
Destiny Pharma plc
Debra Barker, CEO
Shaun Claydon, CFO
+44 (0)1273 704 440
pressoffice@destinypharma.com
Optimum Strategic Communications
Mary Clark / Nick Bastin / Manel Mateus / Eleanor Cooper
+44 (0) 203 922 0891
DestinyPharma@optimumcomms.com
finnCap Ltd (Nominated Advisor and Joint Broker)
Geoff Nash / George Dollemore, Corporate Finance
Alice Lane / Nigel Birks / Harriet Ward, ECM
+44 (0) 207 220 0500
Shore Capital (Joint Broker)
Daniel Bush / James Thomas / Lucy Bowden
+44 (0) 207 408 4090
MC Services AG
Anne Hennecke / Andreas Burckhardt
+49-211-529252-12
About Destiny Pharma
Destiny Pharma is a clinical stage, innovative biotechnology
company focused on the development of novel medicines that can
prevent life-threatening infections. Its pipeline has novel
microbiome-based biotherapeutics and XF drug clinical assets
including NTCD-M3, a Phase 3 ready treatment for the prevention of
C. difficile infection (CDI) recurrence which is the leading cause
of hospital acquired infection in the US and also XF-73 nasal gel,
which has recently completed a positive Phase 2 clinical trial
targeting the prevention of post-surgical staphylococcal hospital
infections including MRSA. It is also co-developing SPOR-COVTM, a
novel, biotherapeutic product for the prevention of COVID-19 and
other viral respiratory infections and has earlier grant funded XF
drug research projects.
For further information on the company, please visit
www.destinypharma.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TVRUNSNROOUBRAR
(END) Dow Jones Newswires
July 07, 2023 02:00 ET (06:00 GMT)
Destiny Pharma (LSE:DEST)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Destiny Pharma (LSE:DEST)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024